Earnings
Telix Pharmaceuticals Hits 52-Week High on Strong Half Results
Telix Pharmaceuticals ADR surged to $12.48, its 52-week peak, after reporting a 22% revenue rise and 146% EBITDA jump in H1 2026.
Booking Holdings posts $9.5B cash flow, AI rollout plans at Goldman Sachs conference
Booking Holdings reported $9.54 billion in levered free cash flow, $7.3 billion of share repurchases and outlined AI trip‑planning tools and loyalty‑program impact.
Repligen Raises Full-Year Growth Outlook, Eyes $1B BioLife Revenue by 2027
Repligen reported 13% organic growth in Q2 2026, raised full-year guidance to 10.5%-13.5%, and outlined strong fundamentals across its protein A, process analytics, and filtration franchises.
HP Shares Hit 52-Week High After Fiscal Q3 Beat
HP stock rose to a 52-week high of $32.85 after posting third-quarter revenue of $15.7 billion and EPS of $0.83, both well above expectations, and raising full-year guidance.
Snowflake Climbs After Strong Quarter, Analysts Raise Price Targets
Snowflake posted a third consecutive quarter of revenue growth acceleration fueled by AI-driven data migrations, prompting Rosenblatt and peers to lift targets.
SEALSQ Reports 131% Revenue Growth, Sees Post-Quantum Demand in 2027
SEALSQ Corp posted 131% revenue growth on ASIC and acquisition gains, widened an operating loss to $32.2M and guided fiscal 2026 revenue of $27M-$36M.
D’Ieteren Group posts 8% profit rise in H1 2026, Belron drives growth as automotive unit slows
Adjusted profit before tax grew 8.4% to EUR 482 million in the first half of 2026, helped by strong Belron performance, while D’Ieteren Automotive saw a 67% profit decline.
Ardent Health Margin Push Accelerates With $70M IMPACT Savings in 2026
The hospital operator reported surgical-headroom write-downs offset by pace-increasing efficiency gains and a shift to national payer contracting yielding mid-single-digit rate lifts.
Choice Hotels Raises Full-Year Growth Outlook on Cost Relief and Brand Push
Choice Hotels lifted its net rooms growth forecast to 1.5% and signaled a return to historical expansion rates, driven by franchise cost reductions and a record share-buyback program.
Korn Ferry Reports Q1 FY27 Earnings, Tops Estimates on AMS Integration
The talent consulting firm posted adjusted EPS of $1.43 and $756 million in fee revenue, extending its growth streak to six straight quarters.
Marvell Raises Combined FY2027-28 Revenue Outlook to $30 Billion on AI Demand
Marvell Tech lifts its two-year combined revenue forecast to $30 billion from $20 billion, citing accelerating data-center and custom-ASIC demand driven by AI infrastructure build-out.
ADM Raises Full-Year EPS Outlook, Highlights Growth and Cost Cuts
Archer Daniels Midland lifted its 2024 adjusted earnings per share guide to $5.15–$5.60 for the second time this year, citing strong Q2 results and a broad cost-reduction program targeting up to $750 million in savings.
Seaport Therapeutics Reports Positive Phase 1 Results for GlyphAllo
The Boston-based biotech said its oral allopregnanolone prodrug cleared a driving-impairment benchmark in healthy volunteers, clearing a hurdle ahead of a Phase 2b study in major depression.
Ducommun Outlines Margin Push, Vision 2032 Strategy at Jefferies Conference
Ducommun CEO Steve Oswald previews updated financial targets for September, highlighting aftermarket growth and defense-commercial revenue rebalancing at the Jefferies Global Industrials Conference.
BD Raises Full-Year Outlook as China Headwinds Ease, Alaris Impact Fades
Becton, Dickinson lifts fiscal 2026 guidance to the high end of low single-digit growth after Q3 organic revenue climbed 4.4%, citing improving margin trajectory and stabilizing China exposure.
Korn Ferry Beats Q1 Estimates but Shares Slip on Mixed Outlook
The executive search firm reported a 9% rise in adjusted EPS to $1.43 and seventh consecutive quarter of revenue growth, but shares dipped in premarket trading after guidance reflected limited early contributions from its Alexander Mann Solutions acquisition.
NeuroPace Touts Growth, Clinical Data, FDA Path at Cantor Conference
NeuroPace reported 33% revenue growth over the past year, strong margins, and outlined its FDA strategy for expanding its RNS therapy to treat idiopathic generalized epilepsy.
Richemont Shareholders Approve Dividends, Board Elections at AGM
Luxury-goods giant pays CHF 4.30 per A-share dividend and renews its board at the 2026 annual meeting in Geneva.
Earnings call transcript: Galliford Try H2 2026 profit, cash and buyback lift shares
Finance Review Daily is tracking this developing story; further verified details were not immediately available.
NXP Raises Outlook on Physical AI Push at Goldman Sachs Conference
NXP Semiconductors lifted its third-quarter margin outlook and reiterated long-term growth targets, citing surging demand across automotive and data center segments driven by the emergence of physical AI and humanoid robotics.
Trex Raises Full-Year Growth Outlook, Outlines $2B Revenue Road Map
Composite decking maker Trex lifted its full-year growth guidance to a 5% midpoint from 3%, citing improving market conditions and a $500 million new manufacturing facility expected to drive long-term cost gains.
Estée Lauder Turnaround Gains Momentum at Barclays Conference
The Estée Lauder Companies reported 5% sales growth and 66% diluted EPS growth in fiscal 2026, with management projecting 3–5% organic growth and margin expansion of 150–230 basis points next year.
Kraft Heinz reports progress in turnaround at Barclays conference
Kraft Heinz CEO Steve Cahillane discusses company's turnaround progress, reinvestment plans, and brand performance at Barclays Global Consumer Conference.
Shenandoah Shifts Fiber Build Priority to Cash Flow Ahead of 2027 Inflection
The broadband operator says it will pivot construction spending after 2024 completions, targeting free cash flow positivity by 2027 as penetration climbs toward 37% in mature markets.